MedPath

Tagged News

First European Patients Receive Accelerator-Based Boron Neutron Capture Therapy for Head and Neck Cancer

Targeted TherapyOncology
  • Helsinki University Hospital and Neutron Therapeutics have treated the first European patients with accelerator-based boron neutron capture therapy (BNCT), marking the first clinical application outside of Asia.
  • BNCT is a targeted radiation therapy that uses epithermal neutrons to activate boron compounds in tumor cells, delivering precise treatment in just one or two sessions while sparing healthy tissue.
  • The milestone treatment is part of a ten-patient clinical trial for locally recurrent head and neck cancer using Neutron Therapeutics' nuBeam® system, with plans to expand availability throughout Europe and the United States.

Alectinib Plus Bevacizumab Shows Promising Results in First-Line Treatment of ALK-Positive NSCLC

Precision MedicineOncologyTargeted Therapy
  • The ALEK-B phase 2 trial demonstrated that combining alectinib with bevacizumab significantly improved progression-free survival in ALK-positive NSCLC patients, with 97% remaining progression-free at 12 months and 64% at 36 months.
  • The combination therapy showed remarkable efficacy in preventing CNS progression, with a 36-month intracranial progression-free survival rate of 87.8% and only 8.8% cumulative incidence of new brain metastases.
  • Despite higher rates of adverse events compared to alectinib monotherapy, particularly proteinuria (70.7%) leading to bevacizumab discontinuation in 43.9% of patients, the treatment maintained quality of life improvements throughout the study period.

Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

NCT05200481Active, Not RecruitingPhase 2
Intergroupe Francophone de Cancerologie Thoracique
Posted 5/18/2022

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

NCT03779191CompletedPhase 2
Instituto Nacional de Cancerologia de Mexico
Posted 4/8/2020

Rakovina Therapeutics Secures $4M Strategic Financing to Advance AI-Powered Cancer Drug Discovery Platform

AIDrug DiscoveryOncology
  • Rakovina Therapeutics announced a strategic $4 million financing round anchored by $3 million from strategic investors to support its AI-powered oncology drug discovery platform.
  • The company will implement a 10-for-1 share consolidation to enhance its capital structure and position for accelerated growth in U.S. capital markets.
  • The financing will support Rakovina's proprietary DNA Damage Response platform targeting treatment-resistant cancers with impaired DNA repair pathways.
  • The company aims to advance its pipeline of DNA-damage response inhibitors toward human clinical trials through pharmaceutical partnerships.

Biodesix Presents New Data Showing Nodify Lung® Tests Improve Pulmonary Nodule Management

Real World EvidenceOncology
  • New study of over 350,000 patients reveals significant gaps in lung nodule management, with approximately two-thirds receiving no clinical work-up after nodule discovery.
  • Research presented at ISPOR 2025 shows concerning rates of mismanagement, with 60% of biopsies performed on benign nodules and 35% of malignant nodules receiving only follow-up CT scans.
  • Real-world data from a safety-net hospital demonstrates how Biodesix's Nodify Lung® testing can guide clinical decisions through actionable results in pulmonary nodule risk stratification.

Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects

NCT03289780Active, Not Recruiting
Biodesix, Inc.
Posted 4/4/2016

Avacta's pre|CISION Technology Makes Toxic Chemotherapy Safer and More Effective

Targeted TherapyOncology
  • Avacta has developed a novel "masked" chemotherapy approach called pre|CISION that dramatically improves safety profiles of toxic cancer drugs while maintaining therapeutic efficacy.
  • The technology works by rendering chemotherapy inactive in normal tissues and only activating the drug when it reaches the tumor microenvironment, significantly reducing systemic toxicity.
  • Clinical applications of pre|CISION technology could potentially transform cancer treatment by allowing higher dosing of potent chemotherapeutics and expanding treatment options for patients who cannot tolerate conventional chemotherapy.

China Approves Xuanyuening (Bireociclib): First Dual-Indication CDK Inhibitor for Advanced Breast Cancer

Drug ApprovalTargeted TherapyOncology
  • China's NMPA has approved Xuanzhu Biopharm's Bireociclib (Xuanyuening®), a novel multi-target CDK inhibitor for HR+/HER2- advanced breast cancer with dual indications.
  • The drug can be used in combination with fulvestrant after endocrine therapy failure and is the only CDK4/6 inhibitor approved in China as monotherapy for heavily pretreated patients.
  • Clinical trials showed impressive efficacy with median PFS of 17.5 months in combination therapy and 11 months as monotherapy, addressing specific needs of Chinese breast cancer patients.

A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

NCT05077449Active, Not RecruitingPhase 3
Xuanzhu Biopharmaceutical Co., Ltd.
Posted 11/16/2021

A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors

NCT04539496Unknown StatusPhase 1
Sihuan Pharmaceutical Holdings Group Ltd.
Posted 5/22/2018

Innate Pharma's Novel NK Cell Engager IPH6501 to Be Presented at EHA 2025 Congress

Oncology
  • Innate Pharma's IPH6501, a tetraspecific NK cell engager targeting CD20 B cells for Non-Hodgkin Lymphoma, will be featured at the European Hematology Association Congress in June 2025.
  • The ANKET® platform technology represents a new class of cancer immunotherapies that co-engage multiple receptors on NK cells while targeting tumor antigens, potentially offering superior efficacy to existing antibody treatments.
  • Preclinical data has shown IPH6501 demonstrates better anti-tumor efficacy than approved benchmark antibodies, with the compound currently being evaluated in a Phase 1/2 trial for relapsed/refractory CD20-expressing B-cell lymphomas.

A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients with Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma

2023-506976-28-00RecruitingPhase 1/2
Innate Pharma

Camber Pharmaceuticals Launches Temozolomide Capsules for Brain Cancer Treatment

Oncology
• Camber Pharmaceuticals has announced the launch of Temozolomide Capsules, USP, an alkylating drug used in the treatment of glioblastoma and anaplastic astrocytoma in adults.
• The medication will be available in five different strengths (5mg, 20mg, 100mg, 140mg, 180mg, and 250mg) and in various count options to support different treatment regimens.
• Temozolomide is primarily used as a concurrent treatment with radiotherapy for newly diagnosed glioblastoma patients, followed by maintenance therapy, addressing critical needs in brain cancer treatment.

Hengrui Pharmaceuticals Aims to Raise $1.27 Billion in Hong Kong IPO

Oncology
  • Chinese pharmaceutical giant Jiangsu Hengrui plans to raise up to $1.27 billion in its Hong Kong IPO, making it one of the city's largest offerings this year.
  • The Shanghai-listed company, which focuses on oncology and metabolic diseases, has secured GIC, Invesco, and Hillhouse as cornerstone investors ahead of its expected May 23 trading debut.
  • Hengrui's offering comes amid a surge in Hong Kong's IPO market, with funds raised from new listings nearly quadrupling in the first quarter compared to last year.

GenVivo Reports Promising Phase 1 Data for GEN2 and Preclinical Results for GEN-1013 Cancer Immunotherapies at ASGCT 2025

Oncology
  • GenVivo's lead candidate GEN2, a non-replicating mRNA vector therapy, demonstrates favorable safety profile with minimal toxicity and encouraging pharmacodynamic activity in Phase 1 trials for solid tumors.
  • GEN-1013, the company's preclinical IL-12 encoding therapy, showed remarkable efficacy in murine cancer models with 89% of treated animals reaching study endpoints compared to just 11% in control groups.
  • Both therapies leverage GenVivo's innovative vector platform that activates patients' immune systems against their own tumor antigens, with GEN-1013 advancing toward IND filing by mid-2026.

Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors

NCT06391918RecruitingPhase 1
GenVivo, Inc.
Posted 3/4/2024

GEN2 Directed Cancer Immunotherapy Trial

NCT04313868CompletedPhase 1
GenVivo, Inc.
Posted 6/13/2014

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.